RGD DISEASE ONTOLOGY - ANNOTATIONS
RGD uses the Human Disease Ontology (DO, https://disease-ontology.org/) for disease curation across species. RGD automatically downloads each new release of the ontology on a monthly basis. Some additional terms which are required for RGD's curation purposes but are not currently covered in the official version of DO have been added. As corresponding terms are added to DO, these custom terms are retired and the DO terms substituted in existing annotations and subsequently used for curation.
Term: Hyperemia
Accession: DOID:9009039
browse the term
Definition: The presence of an increased amount of blood in a body part or an organ leading to congestion or engorgement of blood vessels. Hyperemia can be due to increase of blood flow into the area (active or arterial), or due to obstruction of outflow of blood from the area (passive or venous).
Synonyms: exact_synonym: Active Hyperemia; Arterial Hyperemia; Hyperemias; Passive Hyperemia; Reactive Hyperemia; Reactive Hyperemias; Venous Congestion; Venous Engorgement
primary_id: MESH:D006940 ; RDO:0005835
For additional species annotation, visit the
Alliance of Genome Resources .
G
Ada
adenosine deaminase
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:2502780 PMID:7949234
NCBI chr 3:160,115,840...160,139,947
Ensembl chr 3:160,115,842...160,139,947
G
Adcyap1
adenylate cyclase activating polypeptide 1
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:8637627
NCBI chr 9:121,705,897...121,725,736
Ensembl chr 9:121,706,979...121,725,716
G
Adipoq
adiponectin, C1Q and collagen domain containing
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:12860835
NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
G
Adrb1
adrenoceptor beta 1
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:17345787
NCBI chr 1:277,537,585...277,538,985
Ensembl chr 1:277,537,585...277,538,985
G
Agt
angiotensinogen
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:15815331
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
G
Bdkrb2
bradykinin receptor B2
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:11837250
NCBI chr 6:129,399,468...129,429,676
Ensembl chr 6:129,399,468...129,429,676
G
Cat
catalase
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:10792963
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
G
Cnr2
cannabinoid receptor 2
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:27611972
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
G
Egln1
egl-9 family hypoxia-inducible factor 1
ISO
RGD
PMID:18096761
RGD:11251770
NCBI chr19:57,660,194...57,701,158
Ensembl chr19:57,662,278...57,699,113
G
Hrh3
histamine receptor H3
IDA
RGD
PMID:15381834
RGD:1626431
NCBI chr 3:175,474,310...175,479,395
Ensembl chr 3:175,473,078...175,479,395
G
Il1b
interleukin 1 beta
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:8846404
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
G
Kng2
kininogen 2
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:11837250
NCBI chr11:81,509,185...81,516,759
G
Lipc
lipase C, hepatic type
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:16330034
NCBI chr 8:77,272,582...77,398,485
Ensembl chr 8:77,272,570...77,398,248
G
Nos2
nitric oxide synthase 2
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:12646421
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
G
Nos3
nitric oxide synthase 3
ISO
DNA:SNP: :894G>T (human)
RGD
PMID:11668050
RGD:7777102
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
G
Ptgs2
prostaglandin-endoperoxide synthase 2
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:11820457
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
G
Tac1
tachykinin, precursor 1
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:7507874 PMID:10564113
NCBI chr 4:33,638,853...33,646,819
Ensembl chr 4:33,638,709...33,646,819
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all